MICROPORT NEUROTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.08 HKD | +0.89% |
|
-1.20% | -25.82% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.82% | 671M | - | ||
| +12.05% | 128B | A- | ||
| -9.24% | 10.88B | A- | ||
| -0.49% | 8.76B | C | ||
| +36.99% | 5.48B | B+ | ||
| +8.02% | 3.43B | C- | ||
| -10.32% | 2.76B | B- | ||
| -12.70% | 2.06B | - | - | |
| -13.26% | 1.92B | - | ||
| -27.86% | 1.65B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2172 Stock
- Ratings MicroPort NeuroTech Limited
